Help us reach $1,000,000! Match My Donation

Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

img_table1_Mabs.pngMonoclonal antibodies (mAbs) are specifically designed to target cancer cells

How does it work?

  • mAbs are a special type of protein designed to target antigens, or markers, located on the surface of cancer cells
  • Antibodies locate antigens and recruit immune cells to attack
  • mAbs can also interfere with cell signaling, helping to block growth and communication of tumor cells

For which cancers is it currently used or being studied?

Immunotherapy mAbs are approved by the FDA for a wide range of cancers including:

  • Breast (Herceptin®, Kadcyla®, Perjeta®) 
  • Hodgkin’s lymphoma (Adcetris®)
  • Non-Hodgkin’s lymphoma (Rituxan®, Zevalin®)
  • Colorectal (Avastin®, Erbitux®, Vectibix®)
  • Lung (Avastin®, Cyramza®)
  • Chronic lymphocytic leukemia (Gazyva®, Campath®, Rituxan®, Arzerra®)
  • Gastric (Herceptin®, Cyramza®)
  • Kidney (Avastin®)
  • Brain (Avastin®)
  • Cervical (Avastin®)
  • Ovarian (Avastin®)
  • Acute lymphoblastic leukemia (Blincyto®)

Several mAbs are currently in clinical trials for a wide variety of cancer types:

  • Bavituximab (breast, liver, lung, melanoma, pancreatic, rectal)
  • Ch14.18 (neuroblastoma)
  • Rilotumumab (fallopian, gastric, ovarian)

*Immunotherapy results may vary from patient to patient.

Contact Us

Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Patient education information supported by a charitable donation from Bristol-Myers Squibb Company.